🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the battle against superbug strains of the pathogen, according to health experts.

An International Challenge

Gonorrhoea infections are escalating globally, with figures suggesting more than 82 million infections each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Outcomes and Worldwide Availability

Based on data released by a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which combines two antibiotics. The study involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Doctors directly involved have expressed hope. Access to a single-dose, oral treatment of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.